CEO and Associate Professor of the Singapore Clinical Research Institute (SCRI) Yee Leong Teoh explains the organization’s pivotal role in supporting and developing Singapore’s clinical research landscape, how these efforts have impacted studies from a regional perspective, and his outlook on what direction the country must now take to sustain its future value proposition.
As an introduction for our readers, can you please provide an overview of the SCRI’s functional role and responsibilities?
As an academic institute we support investigator-led studies that private pharmaceutical companies may not be interested because of the low potential profits. However, the substantial impact that these discoveries can have on patients is nevertheless indisputable.
